[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636887":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":26,"locations":33,"responsibleParty":49,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":74,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with thymoma and MG-related antibodies",null,"Patients with histologically or radiologically confirmed thymoma and presence of MG-related antibodies (AChR), with or without clinically manifest myasthenia gravis.",{"label":13,"type":10,"description":14,"interventionNames":10},"Patients with other thymic abnormalities and MG-related antibodies","Patients with non-thymomatous thymic pathology (e.g., thymic hyperplasia) and presence of MG-related antibodies (AChR), with or without clinically manifest myasthenia gravis.",{"label":16,"type":10,"description":17,"interventionNames":10},"Thymoma patients without MG-related antibodies","Patients with confirmed thymoma, negative for MG-related antibodies, and without clinical signs or diagnosis of myasthenia gravis.",{"label":19,"type":10,"description":20,"interventionNames":10},"Patients with established MG without thymic abnormalities","Patients with an established diagnosis of myasthenia gravis based on clinical, serological, and\u002For neurophysiological criteria, and no evidence of thymic abnormalities.",[22],{"name":23,"affiliation":24,"role":25},"Stefano C Previtali","IRCCS Ospedale San Raffaele","PRINCIPAL_INVESTIGATOR",[27,31],{"name":23,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","0039 0226433036","neuromuscolare@hsr.it",{"name":32,"role":28,"phone":29,"phoneExt":10,"email":30},"Benedetta Sorrenti",[34],{"facility":24,"status":10,"city":35,"state":10,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Milan","20132","Italy","IT",{"type":40,"coordinates":41},"Point",[42,43],9.18951,45.46427,{"lat":43,"lon":42},[46,47],{"name":23,"role":28,"phone":29,"phoneExt":10,"email":30},{"name":32,"role":28,"phone":48,"phoneExt":10,"email":30},"0226433036",{"type":25,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Stefano Previtali","Principal Investigator, Head Neuromuscular Repair Research Unit","100636887","thymic-disease-autoimmunity-and-neuromuscular-junction-integrity-in-myasthenia-gravis-100636887",false,"NCT07571525","Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis","Thymic Disease, Autoimmunity, and Neuromuscular Junction Integrity in Myasthenia Gravis: An Observational Prospective Translational Cohort Study","TAILOR-MG","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent\n* Ability to provide written informed consent and comply with study procedures\n* Availability of a serum sample for testing MG-related antibodies\n* Availability of chest imaging (CT and\u002For MRI) to classify thymic status\n\nParticipants must also meet the criteria for at least one of the following study groups:\n\nCohort 1: Thymoma with MG-related antibodies\n\n* Histologically or radiologically confirmed thymoma\n* Presence of at least one pathogenic MG-related antibody (AChR)\n* Presence or absence of clinically manifest myasthenia gravis\n\nCohort 2: Other thymic abnormalities with MG-related antibodies\n\n* Imaging or histological evidence of non-thymomatous thymic pathology (e.g., thymic hyperplasia)\n* Presence of at least one pathogenic MG-related antibody (AChR)\n* Presence or absence of clinically manifest myasthenia gravis\n\nCohort 3: Thymoma without MG-related antibodies\n\n* Histologically or radiologically confirmed thymoma\n* Negative for pathogenic MG-related antibodies (AChR)\n* No clinical diagnosis or symptoms suggestive of myasthenia gravis\n\nCohort 4: Myasthenia gravis without thymic abnormalities\n\n* Established clinical diagnosis of myasthenia gravis with consistent clinical features, supported by at least one of the following:\n\n  1. Seropositivity for MG-related antibodies (AChR, MuSK, or LRP4), or\n  2. Abnormal neuromuscular transmission demonstrated by SFEMG or RNS, or\n  3. Improvement of MG signs with treatment such as oral acetylcholinesterase inhibitors, plasma exchange, IVIg, or corticosteroids\n* Absence of thymic abnormalities on CT or MRI\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Other neuromuscular diseases that could interfere with interpretation of clinical or neurophysiological findings\n* Severe uncontrolled systemic illness that, in the investigator's judgment, may limit participation or confound study outcomes\n* Any medical or psychiatric condition, or history of substance abuse, that may compromise adherence to study procedures\n* Pregnancy or breastfeeding","ALL","18 Years",{"count":63,"type":64},40,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to investigate the clinical, immunological, and neuromuscular features associated with the development and progression of myasthenia gravis (MG) in adult patients with thymic abnormalities and\u002For MG-related antibodies, including individuals with or without clinically manifest disease.\n\nThe main questions it aims to answer are:\n\n* Whether integrated clinical, serological, and histopathological profiles are associated with the presence of MG and can predict disease onset or progression\n* Wheter systemic immune markers are associated with disease activity, progression, and neuromuscular junction alterations\n\nParticipants will:\n\n* Undergo clinical, neurological, and neurophysiological assessments at baseline and during follow-up\n* Provide blood samples for serological and immunological analyses\n* Provide thymic tissue and residual intercostal muscle samples (when undergoing clinically indicated thymectomy) for research analyses\n* Attend follow-up visits at 6, 12, and 18 months\n* Record daily symptoms using an electronic patient-reported outcome tool (for participants with MG)",[68,69,70],"Myasthenia Gravis (MG)","Myasthenia Gravis Associated With Thymoma","Thymoma",[72,73],"myasthenia gravis","thymoma","NOT_YET_RECRUITING","2026-04-30",{"date":77,"type":78},"2026-05-06","ACTUAL",{"date":80,"type":64},"2026-09-15",{"date":82,"type":64},"2029-12-01",{"name":5,"class":6},1]